BioSpace News Archive

Myovant Sciences and Accord Healthcare, Ltd. announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India.

R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance for healthcare providers, and ScionHealth have entered into an agreement that will make R1 the exclusive provider of revenue cycle management (RCM) services for ScionHealth’s 61 long-term acute care hospitals (LTACHs).

Eagle Pharmaceuticals, Inc. announced financial results for the three months ended March 31, 2022.

Protalix BioTherapeutics, Inc. announced that it will release its financial results for the first quarter 2022 and provide a business update on Monday, May 16, 2022.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S.

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults.

Tango Therapeutics, Inc. announced that members of the management team are scheduled to participate in a fireside chat at the Guggenheim Synthetic Lethality Day 2022 on Monday, May 16 at 10:00AM ET.

Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.

Mereo BioPharma Group plc today announced positive top-line efficacy and safety results from “ASTRAEUS” a Phase 2 study of the investigational oral neutrophil elastase (NE) inhibitor, alvelestat (MPH-966).

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced the completion of its U.S. acquisition of Sunosi® from Jazz Pharmaceuticals.